BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
High-dose chemotherapy before autologous transplantation is a therapeutic option as consolidation in primary or relapsed lymphoma. Even if BEAM conditioning is generally used, alternative conditioning regimens have been published. The purpose of this study was to assess the outcome of 177 adult patients with lymphoma whose conditioning treatment included a BAM (busulfan, aracytine, and melphalan) regimen. With a median follow-up of 17.4 months, 2-year estimates of overall survival and progression-free survival for the entire group were 87% and 70.5%, respectively. Mucositis was the main reported complications and infectious episodes were described in 80.2% of patients. According to multivariate analysis, high performance status and age at diagnosis were adverse factors for survival and increased the risk of disease relapse and death. Despite its limitations, this retrospective study suggests that BAM combination is a valid conditioning regimen in lymphoma patients, with an acceptable rate of toxicity.
KeywordsAutologous transplantation Conditioning regimen BEAM BAM Lymphoma
Compliance with ethical standards
Conflict of interest
EG received research support from Pierre Fabre. The remaining authors declare that they have no conflict of interest.
This study was approved by the SFGM-TC scientific council and performed according to the SFGM-TC guidelines and in accordance with the principles of the declaration of Helsinki.
Informed consent was obtained from all subjects.
- 1.Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545. https://doi.org/10.1056/NEJM199512073332305 CrossRefGoogle Scholar
- 2.Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 13:588–595. https://doi.org/10.1200/JCO.19184.108.40.2068 CrossRefGoogle Scholar
- 5.Chen Y-B, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf MD, Artz AS, Bredeson CN, Cooke KR, Ho VT, Lazarus HM, Olsson RF, Saber W, McCarthy PL, Pasquini MC (2015) Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 21:1046–1053. https://doi.org/10.1016/j.bbmt.2015.02.005 CrossRefGoogle Scholar
- 6.Salar A, Sierra J, Gandarillas M, Caballero MD, Marín J, Lahuerta JJ, García-Conde J, Arranz R, León A, Zuazu J, García-Laraña J, López-Guillermo A, Sanz MA, Grañena A, García JC, Conde E, GEL/TAMO Spanish Cooperative Group (2001) Autologous stem cell transplantation for clinically aggressive non-Hodgkin’s lymphoma: the role of preparative regimens. Bone Marrow Transplant 27:405–412. https://doi.org/10.1038/sj.bmt.1702795 CrossRefGoogle Scholar
- 7.Jo J-C, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C (2007) BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 87:43–48. https://doi.org/10.1007/s00277-007-0360-0 CrossRefGoogle Scholar
- 9.Isidori A, Christofides A, Visani G (2016) Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk Lymphoma 57:2499–2509. https://doi.org/10.1016/S0140-6736(15)60165-9 CrossRefGoogle Scholar
- 10.Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, Voilat L, Devidas A, Morschhauser F, Rohrlich P, André M, Lepage E, Ferme C, SFGM/GELA Study Group (1999) Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin’s disease (HD). SFGM/GELA study group. Ann Oncol 10:1485–1488CrossRefGoogle Scholar
- 12.Puig N, de la Rubia J, Remigia MJ et al (2009) Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 47:1488–1494. https://doi.org/10.1038/sj.bmt.1704110 CrossRefGoogle Scholar
- 14.Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS, Park CJ, Huh J, Suh C (2011) BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res 35:183–187. https://doi.org/10.1016/j.leukres.2010.07.016 CrossRefGoogle Scholar
- 15.Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, Horowitz M, Fisher R, Tomblyn M (2013) Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 31:1662–1668. https://doi.org/10.1200/JCO.2012.45.9453 CrossRefGoogle Scholar
- 16.Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB (2013) Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 19:410–417. https://doi.org/10.1016/j.bbmt.2012.10.029 CrossRefGoogle Scholar
- 17.Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L, Vidriales B, Cañizo MC, Corral M, Gonzalez M, León A, Jean-Paul E, Rocha E, Moraleda JM, Miguel JFS (1997) BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 20:451–458. https://doi.org/10.1038/sj.bmt.1700913 CrossRefGoogle Scholar
- 18.Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M, Baker KS, Fung H, Gurney JG, McGlave P, Nademanee A, Ramsay NK, Stein A, Weisdorf DJ, Forman SJ (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 105:4215–4222. https://doi.org/10.1182/blood-2005-01-0035 CrossRefGoogle Scholar